Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

From The Lancet Correspondence. In the opening to the 2019 World Malaria Report, entitled Leaving no one behind in the march to a malaria free world, the WHO’s Director-General notes that the scourge of malaria continues to strike hardest against pregnant women and children in Africa.

Health care workers sharing information about malaria to locals © 2020 MORU. Photographer: Mehul Dhorda.
Women being recruited for a malaria study in Kinshasa

WHO’s Director-General reports that “some 11 million pregnant women in sub- Saharan Africa were infected with malaria and, consequently, nearly 900 000 children were born with a low birthweight.” Furthermore, he notes that “Malaria in pregnancy compromises the mother’s health and puts her at greater risk of death. It impacts the health of the fetus, leading to prematurity and low birthweight, major contributors to neonatal and infant mortality.”1

In sub-Saharan Africa, Plasmodium falciparum is responsible for an estimated 50,000 maternal deaths and 200,000 stillbirths each year, in addition to substantial adverse neonatal morbidity (preterm birth and small-for-gestational-age) predisposing to death in infancy and non-communicable diseases in later life.2 This intolerable carnage is preventable.

Artemisinin combination treatments (ACTs) are first-line treatments for falciparum malaria throughout the world, and they are recommended by WHO as the treatment of choice for women in the second and third trimesters of pregnancy, but puzzlingly they are still not recommended by WHO in the first trimester. Concerns over the use of artemisinin derivatives in the first trimester have been systematically addressed.2,3 In 2015 an Evidence Review Group convened by the WHO’s Global Malaria Programme (WHO GMP) reported a detailed review of all available data and recommended that the clear benefits exceeded any potential risks and that ACTs should be used to treat uncomplicated falciparum malaria in the first trimester.

The WHO GMP’s own malaria policy advisory group then recommended “review of the WHO Guidelines for the treatment of malaria to consider the timely inclusion of ACT as a first-line therapeutic option for uncomplicated falciparum malaria”,4 a process WHO GMP initiated through its Treatment Guidelines Committee in 2017. Yet today, well over 4 years after the original recommendation, WHO still recommends quinine, a drug for which there are few data on safety in the first trimester. Quinine is poorly tolerated, poorly adhered to, and therefore less effective than ACTs.2,3 Hospitals, antenatal clinics, and malaria control programmes all have to retain quinine for this one unnecessary indication.5

Why is WHO leaving behind women in the first trimester of pregnancy? Nothing has justified this more than 4-year delay. We urge WHO to heed the advice of the Evidence Review Group and revise its outdated recommendations on the treatment of malaria in early pregnancy as a matter of urgency.

- Rose McGready, François Nosten, Karen I Barnes, Olugbenga Mokuolu, Nicholas J White


Declaration of interests’ statement

KB, OM and NW were all members of the  WHO Technical Expert Group on Malaria Chemotherapy


Shoklo Malaria Research Unit (RM, FN) and Mahidol–Oxford Tropical Medicine Research Unit (RM, FN, NJW), Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand;

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK (RM, FN, NJW);

Division of Clinical Pharmacology and SAMRC Collaborating Centre for Optimising Antimalarial Therapy, Department of Medicine, University of Cape Town, Cape Town, South Africa (KIB); and Department of Paediatrics and Child Health, University of Ilorin Teaching Hospital, Ilorin, Nigeria (OM)


1 WHO. World Malaria Report 2019. 2019. world-malaria-report-2019 (accessed Jan 22, 2020).

2 Saito M, Gilder ME, McGready R, Nosten F. Antimalarial drugs for treating and preventing malaria in pregnant and lactating women. Expert Opin Drug Saf 2018; 17: 1129–44.

3 Dellicour S, Sevene E, McGready R, et al. First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies. PLoS Med 2017; 14: e1002290.

4 WHO Malaria Policy Advisory Committee and Secretariat. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of eighth biannual meeting (September 2015). Malaria J 2016; 15: e117

5 Rao VB, Jensen TO, Jimenez BC, et al. Malaria in pregnancy: a call for a safe, efficient, and patient-centred approach to first-trimester treatment. Lancet Glob Health 2018; 6: e607–08.

Similar stories

All-nighter: staying up to fight malaria

Featured in Nature, Victor Chaumeau collects mosquitoes in Myanmar to better understand how to control malaria.

AMR and scrub typhus among Chiangrai Unit's research priorities

Which infections are most common in the Chiangrai region? How should we treat them and how can we improve diagnostic? Which strategies are most effective in directing antibiotic treatment? Blog by Carlo Perrone, research physician based at the Chiang Rai Clinical Research Unit in Chiangrai, Thailand.

Arjen Dondorp, Peter Horby and Rose McGready elected Academy of Medical Sciences Fellows

"Although it is hard to look beyond the pandemic right now," says President of the Academy of Medical Sciences Professor Dame Anne Johnson, "I want to stress how important it is that the Academy Fellowship represents the widest diversity of biomedical and health sciences. The greatest health advances rely on the findings of many types of research, and on multidisciplinary teams and cross-sector and global collaboration."

Researchers call for access to Ivermectin for young children

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.